Clinical Trials Directory

Trials / Completed

CompletedNCT05352776

Sensing and Defibrillation With a Commercially Available ICD Coupled With a Parasternal Extravascular Lead (SECURE EV) Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
18 (actual)
Sponsor
AtaCor Medical, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The SECURE EV Study is a prospective, multi-center, single-arm study without concurrent or historical controls. The objectives of the study are 1) to characterize safety of the AtaCor EV-ICD Lead up to 90 days post-implant, and 2) to characterize sensing and conversion of induced VF up to 90 days post-implant.

Detailed description

The primary safety objective of the study is to characterize safety of the AtaCor EV-ICD Lead up to 90 days post-implant. The primary performance objective is to characterize sensing and conversion of induced VF up to 90 days post-implant. Up to 3 Investigational Sites Worldwide will participate with up to 20 subjects enrolled in the study. Patients undergoing de novo or replacement ICD procedure will be eligible for participation. Study participation requires sub-chronic evaluation of the lead up to 90 days. Subjects will receive a concomitant EV-ICD System, comprising the investigational EV-ICD Lead connected to a commercially available ICD. Prior to discharge, the EV-ICD will be programmed to monitor only to detect and store ventricular arrhythmias over the 90-day follow-up period. After the EV-ICD System is removed (up to 90 days post-implant), the Subject will be followed for an additional 30 days then exit the study. The duration of study participation for an individual Subject is 120 ± 7 days. The study is expected to complete within 6 months of the first enrollment.

Conditions

Interventions

TypeNameDescription
DEVICEAtaCor EV-ICD LeadSubjects will receive the AtaCor EV-ICD Lead being evaluated in the study.

Timeline

Start date
2022-05-18
Primary completion
2022-09-21
Completion
2022-10-20
First posted
2022-04-29
Last updated
2023-08-29

Locations

1 site across 1 country: Paraguay

Source: ClinicalTrials.gov record NCT05352776. Inclusion in this directory is not an endorsement.